Biotech company partners with National Jewish Health to test potential Covid-19 therapy

For National Jewish Health’s part, joining in this double-blind, placebocontrolled study meant addressing a major need of Covid-19. “There
aren’t really therapeutic options for patients with Covid-19,” said
Michael Wechsler, a pulmonologist at National Jewish Health [and
professor of medicine at CU School of Medicine] who is involved with
the study.